Basic fibroblast growth factor suspended in Matrigel improves titanium implant fixation in ovariectomized rats

Basic fibroblast growth factor (bFGF) has high potential for tissue regeneration; however, its in vivo effects are unpredictable due to the short-term survival. This study sought to evaluate the effects of bFGF suspended in Matrigel on the implant fixation in ovariectomized (OVX) rats. In vitro, the release kinetics of bFGF was tested using an immuno-ligand-assay. In vivo, eighty titanium implants were randomly divided into 4 groups and inserted in the tibiae of forty OVX rats: no treatment group, bFGF alone group, Matrigel alone group and bFGF + Matrigel group. At 3 months after implantation, tibiae were examined by histology, micro-CT and push-out test. We found that Matrigel could prolong the life span of bFGF in vitro with a sustained release during the 21 days. In vivo, bFGF or Matrigel alone had little effect on the fixation of implant in OVX rats, but bFGF suspended in Matrigel induced nearly 2-fold of peri-implant new bone formation and 4-fold of implant mechanical stability when compared to other 3 groups. The results of this study suggest that Matrigel could be used as a carrier of bFGF and prolonged its release around implant, which may improve implant fixation, especially in site of post-menopausal osteoporosis.

bFGF released from Matrigel improved the bone formation around the titanium implant in ovariectomized rats.Figure optionsDownload as PowerPoint slide